Lv11
90 积分 2023-08-04 加入
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
2小时前
待确认
A prospective, single-arm, open-label, phase II clinical trial on efficacy and safety of cadonilimab plus anlotinib for recurrent, metastatic or persistent cervical cancer
2小时前
已完结
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
2小时前
已完结
Cancer of the cervix uteri: 2025 update
5小时前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
1个月前
已完结
Topical sirolimus in dermatology: a systematic review
2个月前
已关闭
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies
4个月前
已完结
Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)
5个月前
已完结
Evolving treatment paradigms for platinum-resistant ovarian cancer: An update narrative review
5个月前
已完结
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
